This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
|Articles|June 1, 2003
- Pharmaceutical Technology-06-01-2003
- Volume 2003 Supplement
- Issue 3
Studying In Vitro Skin Preparation and Drug Release to Optimize Dermatological Formulations
Author(s)Krista Witt
In vitro skin penetration and drug-release studies are the simplest and most cost-effective methods for characterizing a drug's skin absorption and penetration profiles.
Advertisement
Articles in this issue
over 23 years ago
Transdermal Drug Formulation and Process Developmentover 23 years ago
Controlled-Release of Oral Dosage FormsAdvertisement
Related to this article
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Advertisement
Advertisement